数据中心
龙虎榜
大单追踪
资金流向
业绩预告
新股申购
行情中心
沪深市场
香港市场
美国市场
全球市场
行业风云
全球市场
向上 向下

董事介绍

注:董事持股数取自最新公司公告

姓名 性别 职位 年龄 薪酬 持股数(万股) 截止日期
James Hill Director 74 0.0076万美元 未持股 2020-03-31
Stuart Ungar Director 76 6.54万美元 未持股 2020-03-31
David Byrne Director 60 6.54万美元 未持股 2020-03-31
Clive Richardson Director,Chief Executive Officer and Chief Operating Officer 55 77.40万美元 未持股 2020-03-31
Ray Prudo Director,Executive Chairman of the Board 75 31.83万美元 未持股 2020-03-31
Michael Grissinger Director 66 8.52万美元 未持股 2020-03-31
Peter Feldschreiber Director 76 3.64万美元 未持股 2020-03-31
Donald Williams Director 61 6.14万美元 未持股 2020-03-31

高管介绍

注:高管持股数取自最新公司公告

姓名 性别 职位 年龄 薪酬 持股数(万股) 截止日期
Clive Richardson Director,Chief Executive Officer and Chief Operating Officer 55 77.40万美元 未持股 2020-03-31
Ray Prudo Director,Executive Chairman of the Board 75 31.83万美元 未持股 2020-03-31

董事简历

中英对照 |  中文 |  英文
James Hill

James Hill,他目前是我们董事会的成员。加入我们的董事会之前,他曾担任Genetix Group Plc(AIM上市公司,为科学家提供细胞成像和分析智能解决方案)的非执行董事兼主席(2001年至2009年)。此前,他曾担任SmithKline Beecham的董事兼高级公司事务副总裁(1994年至2001年),负责全球投资者关系、政府事务、沟通。他曾担任公司管理团队成员,负责公司战略。


James Hill has served as a member of our board of directors since September 2015. Prior to joining our board of directors, Dr. Hill was a non-executive director and Chairman of Genetix Group Plc from 2001 to 2009 an AIM listed company providing scientists with intelligent solutions for cell imaging and analysis. Previously Dr. Hill was a director and Senior Vice President of Corporate Affairs with SmithKline Beecham, from 1994 to 2001 with global responsibility for Investor Relations, Government Affairs, Communication and was a member of the corporate management team which oversaw corporate strategy. Dr. Hill's prior experience was in the field of strategic product development working closely with research and development and the global markets. Dr. Hill qualified in medicine at Guys Hospital and became a fellow to The Royal Colleges of Physicians in both London and Edinburgh and was earlier awarded a Hunterian Professorship by The Royal College of Surgeons in England.
James Hill,他目前是我们董事会的成员。加入我们的董事会之前,他曾担任Genetix Group Plc(AIM上市公司,为科学家提供细胞成像和分析智能解决方案)的非执行董事兼主席(2001年至2009年)。此前,他曾担任SmithKline Beecham的董事兼高级公司事务副总裁(1994年至2001年),负责全球投资者关系、政府事务、沟通。他曾担任公司管理团队成员,负责公司战略。
James Hill has served as a member of our board of directors since September 2015. Prior to joining our board of directors, Dr. Hill was a non-executive director and Chairman of Genetix Group Plc from 2001 to 2009 an AIM listed company providing scientists with intelligent solutions for cell imaging and analysis. Previously Dr. Hill was a director and Senior Vice President of Corporate Affairs with SmithKline Beecham, from 1994 to 2001 with global responsibility for Investor Relations, Government Affairs, Communication and was a member of the corporate management team which oversaw corporate strategy. Dr. Hill's prior experience was in the field of strategic product development working closely with research and development and the global markets. Dr. Hill qualified in medicine at Guys Hospital and became a fellow to The Royal Colleges of Physicians in both London and Edinburgh and was earlier awarded a Hunterian Professorship by The Royal College of Surgeons in England.
Stuart Ungar

Stuart Ungar,他目前是我们董事会的成员。在英国The Royal Post-Graduate Medical School进行内科研究生学习和神经医药学的研究之后,他曾在伦敦The Princess Grace Hospital担任内科医生进行实践。在15年的实践之后,他和Raymond Prudo先生创立The Doctors Laboratory PLC TDL(综合病理学实验室,在英国和国外为临床医生和医药组织提供分析服务)。在担任董事长和董事会任期时,The Doctors Laboratory PLC从一个初创公司成长为英国最大的病理学实验室之一。2002年其被Sonic Healthcare(一个澳大利亚公司报价)收购。他在the Royal Free Hospital School of Medicine的the University of London学习医学和生物化学。作为研究生,他被The Royal College of Physicians of the United Kingdom认可。他是The Royal Society of Medicine的研究员和The Royal Society of Medicine 的创始人和前副总裁。


Stuart Ungar has served as a member of our board of directors since September 2015. Dr. Ungar is currently a member of our board of directors. After pursuing post-graduate studies in Internal Medicine and research in neuro-pharmacology at The Royal Post-Graduate Medical School, UK, Dr. Ungar was in practice as an Internist at The Princess Grace Hospital, London. Following fifteen years of practice he, jointly with Dr. Raymond Prudo, founded The Doctors Laboratory PLC TDL, a general pathology laboratory, which provided analytical services to clinicians and pharmaceutical organizations throughout the United Kingdom and abroad. During his tenure as Chairman and Board Director, The Doctors Laboratory PLC grew from a start-up to become one of the largest pathology laboratories in the United Kingdom. It was sold to Sonic Healthcare, a quoted Australian PLC in 2002. Dr. Ungar studied medicine and biochemistry in the University of London at the Royal Free Hospital School of Medicine. As a post-graduate he was admitted to The Royal College of Physicians of the United Kingdom. Dr. Ungar is a Life Fellow of The Royal Society of Medicine and a founder and former Vice-President of The Independent Doctors Federation.
Stuart Ungar,他目前是我们董事会的成员。在英国The Royal Post-Graduate Medical School进行内科研究生学习和神经医药学的研究之后,他曾在伦敦The Princess Grace Hospital担任内科医生进行实践。在15年的实践之后,他和Raymond Prudo先生创立The Doctors Laboratory PLC TDL(综合病理学实验室,在英国和国外为临床医生和医药组织提供分析服务)。在担任董事长和董事会任期时,The Doctors Laboratory PLC从一个初创公司成长为英国最大的病理学实验室之一。2002年其被Sonic Healthcare(一个澳大利亚公司报价)收购。他在the Royal Free Hospital School of Medicine的the University of London学习医学和生物化学。作为研究生,他被The Royal College of Physicians of the United Kingdom认可。他是The Royal Society of Medicine的研究员和The Royal Society of Medicine 的创始人和前副总裁。
Stuart Ungar has served as a member of our board of directors since September 2015. Dr. Ungar is currently a member of our board of directors. After pursuing post-graduate studies in Internal Medicine and research in neuro-pharmacology at The Royal Post-Graduate Medical School, UK, Dr. Ungar was in practice as an Internist at The Princess Grace Hospital, London. Following fifteen years of practice he, jointly with Dr. Raymond Prudo, founded The Doctors Laboratory PLC TDL, a general pathology laboratory, which provided analytical services to clinicians and pharmaceutical organizations throughout the United Kingdom and abroad. During his tenure as Chairman and Board Director, The Doctors Laboratory PLC grew from a start-up to become one of the largest pathology laboratories in the United Kingdom. It was sold to Sonic Healthcare, a quoted Australian PLC in 2002. Dr. Ungar studied medicine and biochemistry in the University of London at the Royal Free Hospital School of Medicine. As a post-graduate he was admitted to The Royal College of Physicians of the United Kingdom. Dr. Ungar is a Life Fellow of The Royal Society of Medicine and a founder and former Vice-President of The Independent Doctors Federation.
David Byrne

David Byrne,现任公司董事会成员。自1997年起,Mr. Byrne担任Sonic Healthcare UK Group首席执行官,这是英国最大的非政府组织临床诊断组织。 Mr. Byrne还曾担任CIS Healthcare Limited董事会董事,2000年至2007年担任Clinisys Solutions Ltd财务董事会董事。


David Byrne has served as a member of our board of directors since June 2016. Mr. Byrne is currently Group Chief Executive Officer of Sonic Healthcare UK Group, the United Kingdom’s largest NGO clinical diagnostics organization, a position that he has held since 1997. Mr. Byrne is also the CEO of The Doctors Laboratory which is a subsidiary of Sonic. Mr. Byrne also currently serves as a Main Board Director for CIS Healthcare Limited and served as a Main Board Finance Director for Clinisys Solutions Ltd from 2000 to 2007. He is a UK Chartered Certified Accountant with over 25 years’ experience in corporate finance and developing early stage biotechnology and medical services companies.
David Byrne,现任公司董事会成员。自1997年起,Mr. Byrne担任Sonic Healthcare UK Group首席执行官,这是英国最大的非政府组织临床诊断组织。 Mr. Byrne还曾担任CIS Healthcare Limited董事会董事,2000年至2007年担任Clinisys Solutions Ltd财务董事会董事。
David Byrne has served as a member of our board of directors since June 2016. Mr. Byrne is currently Group Chief Executive Officer of Sonic Healthcare UK Group, the United Kingdom’s largest NGO clinical diagnostics organization, a position that he has held since 1997. Mr. Byrne is also the CEO of The Doctors Laboratory which is a subsidiary of Sonic. Mr. Byrne also currently serves as a Main Board Director for CIS Healthcare Limited and served as a Main Board Finance Director for Clinisys Solutions Ltd from 2000 to 2007. He is a UK Chartered Certified Accountant with over 25 years’ experience in corporate finance and developing early stage biotechnology and medical services companies.
Clive Richardson

Clive Richardson,曾担任我们的首席运营官(2015年9月16日以来)。2014年1月至2015年9月,他曾担任Volution Immuno Pharmaceuticals SA的运营主管,作为顾问。任职Volution Immuno Pharmaceuticals SA之前,他曾担任Varleigh Immuno Pharmaceuticals的顾问(2007年公司创立以来)。任职Volution、Varleigh之前,他曾担任一系列国际医疗保健公司的董事会成员,其中包括CIS Healthcare Ltd.、Clinisys Ltd.。他此前曾担任Investec Bank的前任股票研究主管,也曾担任L.E.K.Consulting的战略顾问。他持有牛津大学三一学院(Trinity College、Oxford University)的动物性硕士学位。


Clive Richardson has served as our Chief Operating Officer and member of our board of directors since September 2015 as our Interim Chief Executive Officer from May 2018 until July 2019 and as our Chief Executive Officer since July 2019. Prior to that, Mr. Richardson was Head of Operations for Volution, a position he has held from January 2014 until September 2015 and before that he was a consultant to Volution’s predecessor company, Varleigh Immuno Pharmaceuticals, since inception in 2007. Prior to working for Volution and Varleigh, Mr. Richardson served as a member of the board of directors for a range of international healthcare companies, including CIS Healthcare Ltd. and Clinisys Ltd. Mr. Richardson was formerly Head of Equities Research for Investec Bank, and worked as a strategy consultant for L.E.K. Consulting. Mr. Richardson holds an M.A. in Zoology from Trinity College, Oxford University.
Clive Richardson,曾担任我们的首席运营官(2015年9月16日以来)。2014年1月至2015年9月,他曾担任Volution Immuno Pharmaceuticals SA的运营主管,作为顾问。任职Volution Immuno Pharmaceuticals SA之前,他曾担任Varleigh Immuno Pharmaceuticals的顾问(2007年公司创立以来)。任职Volution、Varleigh之前,他曾担任一系列国际医疗保健公司的董事会成员,其中包括CIS Healthcare Ltd.、Clinisys Ltd.。他此前曾担任Investec Bank的前任股票研究主管,也曾担任L.E.K.Consulting的战略顾问。他持有牛津大学三一学院(Trinity College、Oxford University)的动物性硕士学位。
Clive Richardson has served as our Chief Operating Officer and member of our board of directors since September 2015 as our Interim Chief Executive Officer from May 2018 until July 2019 and as our Chief Executive Officer since July 2019. Prior to that, Mr. Richardson was Head of Operations for Volution, a position he has held from January 2014 until September 2015 and before that he was a consultant to Volution’s predecessor company, Varleigh Immuno Pharmaceuticals, since inception in 2007. Prior to working for Volution and Varleigh, Mr. Richardson served as a member of the board of directors for a range of international healthcare companies, including CIS Healthcare Ltd. and Clinisys Ltd. Mr. Richardson was formerly Head of Equities Research for Investec Bank, and worked as a strategy consultant for L.E.K. Consulting. Mr. Richardson holds an M.A. in Zoology from Trinity College, Oxford University.
Ray Prudo

Ray Prudo,一直担任医疗保健公司的积极投资者和开发商25年。他一直担任Volution及其前身公司(Varleigh Immuno Pharmaceuticals)的创始人、董事长和首席执行官(2008年公司创立以来)。他目前是一些英国的医疗保健公司的董事会成员。他持有the University of London的内外全科医学士学位,以及the Royal College of Physicians and Surgeons of Canada的成员。


Ray Prudo has served as our Executive Chairman since September 2015. Dr. Prudo has been an active investor and developer of healthcare companies for 25 years. Dr. Prudo is the Founder, Chairman, and Chief Executive Officer of Volution and its predecessor company, Varleigh Immuno Pharmaceuticals, since inception in 2007. He is currently a board member of several UK healthcare companies. Dr. Prudo holds an MBBS from the University of London, and an FRCPC from the Royal College of Physicians and Surgeons of Canada.
Ray Prudo,一直担任医疗保健公司的积极投资者和开发商25年。他一直担任Volution及其前身公司(Varleigh Immuno Pharmaceuticals)的创始人、董事长和首席执行官(2008年公司创立以来)。他目前是一些英国的医疗保健公司的董事会成员。他持有the University of London的内外全科医学士学位,以及the Royal College of Physicians and Surgeons of Canada的成员。
Ray Prudo has served as our Executive Chairman since September 2015. Dr. Prudo has been an active investor and developer of healthcare companies for 25 years. Dr. Prudo is the Founder, Chairman, and Chief Executive Officer of Volution and its predecessor company, Varleigh Immuno Pharmaceuticals, since inception in 2007. He is currently a board member of several UK healthcare companies. Dr. Prudo holds an MBBS from the University of London, and an FRCPC from the Royal College of Physicians and Surgeons of Canada.
Michael Grissinger

Michael Grissinger自2018年11月以来一直担任我们的董事会成员。Grissinger先生目前是制药业务的独立董事和顾问。在1996年1月开始了22年的职业生涯后,他于2018年4月从强生公司退休,2016年4月至2018年4月,他Vice President担任过Vice President并购业务、资产剥离和免疫学业务发展等多个职位,2014年1月至2016年3月为Corporate Development Pharmaceuticals,2002年1月至2013年12月为Vice President Pharmaceutical Business Development and Licensing。在强生公司,他领导的交易和团队涉及广泛的交易类型、地域和治疗性疾病领域。Grissinger先生目前在AkariTherapeutics,Plc和Atrin Pharmaceuticals,Inc.的董事会任职。Grissinger先生拥有Juniata College的化学学士学位和Temple University-Fox School of Business的工商管理硕士学位。


Michael Grissinger has served as a member of board of directors of Adicet Bio, Inc. since November 2018. Mr. Grissinger is currently an independent director and advisor in the pharmaceuticals business. He retired from Johnson & Johnson, Inc. in April 2018 after a 22-year career beginning in January 1996 holding various positions such as Vice President M&A Operations, Divestitures, and Immunology Business Development from April 2016 to April 2018 Vice President, Corporate Development Pharmaceuticals from January 2014 to March 2016 and Vice President Pharmaceutical Business Development and Licensing from January 2002 to December 2013. At Johnson & Johnson, he led transactions and teams across a broad span of deal-types, geographies, and therapeutic disease areas. Mr. Grissinger currently serves on the boards of Akari Therapeutics, plc and Atrin Pharmaceuticals, Inc. Mr. Grissinger holds a B.S. in Chemistry from Juniata College and an M.B.A. from Temple University-Fox School of Business.
Michael Grissinger自2018年11月以来一直担任我们的董事会成员。Grissinger先生目前是制药业务的独立董事和顾问。在1996年1月开始了22年的职业生涯后,他于2018年4月从强生公司退休,2016年4月至2018年4月,他Vice President担任过Vice President并购业务、资产剥离和免疫学业务发展等多个职位,2014年1月至2016年3月为Corporate Development Pharmaceuticals,2002年1月至2013年12月为Vice President Pharmaceutical Business Development and Licensing。在强生公司,他领导的交易和团队涉及广泛的交易类型、地域和治疗性疾病领域。Grissinger先生目前在AkariTherapeutics,Plc和Atrin Pharmaceuticals,Inc.的董事会任职。Grissinger先生拥有Juniata College的化学学士学位和Temple University-Fox School of Business的工商管理硕士学位。
Michael Grissinger has served as a member of board of directors of Adicet Bio, Inc. since November 2018. Mr. Grissinger is currently an independent director and advisor in the pharmaceuticals business. He retired from Johnson & Johnson, Inc. in April 2018 after a 22-year career beginning in January 1996 holding various positions such as Vice President M&A Operations, Divestitures, and Immunology Business Development from April 2016 to April 2018 Vice President, Corporate Development Pharmaceuticals from January 2014 to March 2016 and Vice President Pharmaceutical Business Development and Licensing from January 2002 to December 2013. At Johnson & Johnson, he led transactions and teams across a broad span of deal-types, geographies, and therapeutic disease areas. Mr. Grissinger currently serves on the boards of Akari Therapeutics, plc and Atrin Pharmaceuticals, Inc. Mr. Grissinger holds a B.S. in Chemistry from Juniata College and an M.B.A. from Temple University-Fox School of Business.
Peter Feldschreiber

Peter Feldschreiber自2018年1月以来一直担任我们的董事会成员。Feldschreiber博士拥有医生和大律师的双重资格,在制药业和梦百合法律方面都有丰富的经验。自2004年以来,Feldschreiber博士一直是Lincoln&8217;s Inn的4New Square Chambers的成员。他在制药行业拥有超过20年的经验,包括在宝洁有限公司(Proctor and Gamble Limited)担任10年的欧洲医疗总监,并被任命为英国政府咨询机构人类药物委员会(Commission on Human Medicines)的高级医疗评估师和特别诉讼协调员,以及设备、药品和梦百合产品安全监管机构委员会,后者是英国政府卫生部的一部分。Feldschreiber博士是牛津大学出版社(Oxford University Press)的《药品法律与法规》(Law and Regulation of Medicines)的主编,也是《英国哈尔斯伯里法律》(Halsbury’;s Law of England)第五版医药产品与药品部分的顾问编辑。Dr.Feldschreiber持有B.SC.Kings College Hospital Medical School,University of London的工商管理硕士学位,是皇家医学院(the Faculty of Pharmaceutical Medicine Royal College of Physicians)的研究员,持有法学学士学位。来自泰晤士河谷大学。


Peter Feldschreiber has served as a member of our board of directors since January 2018. Dr. Feldschreiber is dual qualified as a physician and barrister with extensive experience both in the pharmaceutical industry and healthcare law. Since 2004 Dr. Feldschreiber has been a member of 4 New Square chambers in Lincoln’s Inn. He has over 20 years’ experience in the pharmaceutical industry including 10 years’ as European Medical Director at Proctor and Gamble Limited and he has held appointments as Senior Medical Assessor and Special Litigation Coordinator to the Commission on Human Medicines, a U.K. government advisory body, as well as the Committee on Safety of Devices, Medicines, and Healthcare Products Regulatory Agency, part of the U.K. government’s Department of Health. Dr. Feldschreiber is General Editor of the Law and Regulation of Medicines Oxford University Press and Consultant Editor for the section on Medicinal Products and Drugs in the Fifth Edition of Halsbury’s Laws of England. Dr. Feldschreiber holds a B.Sc. MB.BS from Kings College Hospital Medical School, University of London, is a Fellow of the Faculty of Pharmaceutical Medicine Royal College of Physicians and holds an LLB Hons. from Thames Valley University.
Peter Feldschreiber自2018年1月以来一直担任我们的董事会成员。Feldschreiber博士拥有医生和大律师的双重资格,在制药业和梦百合法律方面都有丰富的经验。自2004年以来,Feldschreiber博士一直是Lincoln&8217;s Inn的4New Square Chambers的成员。他在制药行业拥有超过20年的经验,包括在宝洁有限公司(Proctor and Gamble Limited)担任10年的欧洲医疗总监,并被任命为英国政府咨询机构人类药物委员会(Commission on Human Medicines)的高级医疗评估师和特别诉讼协调员,以及设备、药品和梦百合产品安全监管机构委员会,后者是英国政府卫生部的一部分。Feldschreiber博士是牛津大学出版社(Oxford University Press)的《药品法律与法规》(Law and Regulation of Medicines)的主编,也是《英国哈尔斯伯里法律》(Halsbury’;s Law of England)第五版医药产品与药品部分的顾问编辑。Dr.Feldschreiber持有B.SC.Kings College Hospital Medical School,University of London的工商管理硕士学位,是皇家医学院(the Faculty of Pharmaceutical Medicine Royal College of Physicians)的研究员,持有法学学士学位。来自泰晤士河谷大学。
Peter Feldschreiber has served as a member of our board of directors since January 2018. Dr. Feldschreiber is dual qualified as a physician and barrister with extensive experience both in the pharmaceutical industry and healthcare law. Since 2004 Dr. Feldschreiber has been a member of 4 New Square chambers in Lincoln’s Inn. He has over 20 years’ experience in the pharmaceutical industry including 10 years’ as European Medical Director at Proctor and Gamble Limited and he has held appointments as Senior Medical Assessor and Special Litigation Coordinator to the Commission on Human Medicines, a U.K. government advisory body, as well as the Committee on Safety of Devices, Medicines, and Healthcare Products Regulatory Agency, part of the U.K. government’s Department of Health. Dr. Feldschreiber is General Editor of the Law and Regulation of Medicines Oxford University Press and Consultant Editor for the section on Medicinal Products and Drugs in the Fifth Edition of Halsbury’s Laws of England. Dr. Feldschreiber holds a B.Sc. MB.BS from Kings College Hospital Medical School, University of London, is a Fellow of the Faculty of Pharmaceutical Medicine Royal College of Physicians and holds an LLB Hons. from Thames Valley University.
Donald Williams

Donald Williams自2016年6月起担任我们的董事会成员。Williams先生在Ernst & Young 担任18年的合伙人,过去7年担任Grant Thornton的合伙人。Williams先生的职业生涯集中在技术和生命科学领域的私营和上市公司。在Grant Thornton最近7年里,他曾担任Grant Thornton的生命科学实践的领导人和圣地亚哥办事处的执行合伙人。他是Ernst&Young和Grant Thornton在多个首次公开发行上的主要合伙人;二次发行;私人和公共债务融资;以及众多的兼并和收购。2014年开始,Williams 先生担任Marina Biotech, Inc.的董事。从2015年起,他担任Proove Biosciences,Inc。和Alphatec Holdings,Inc。及其全资子公司Alphatec Spine,Inc的董事。2001年至2014年,Williams先生在董事会任职,是 San Diego Venture Group 的前总裁和主席,并曾在他居住的社区的各种慈善组织的董事会任职。Williams先生是Southern Illinois University的毕业生。


Donald Williams has served as a member of our board of directors since June 2016. Mr. Williams is a 35-year veteran of the public accounting industry who retired in 2014. Mr. Williams spent 18 years as a partner at Ernst & Young and the last seven years as a partner at Grant Thornton. Mr. Williams’ career focused on private and public companies in the technology and life sciences sectors. During the last seven years at Grant Thornton, he served as the National Leader of Grant Thornton’s Life Sciences Practice and the Managing Partner of the San Diego Office. He was the lead partner for both Ernst & Young and Grant Thornton on multiple initial public offerings; secondary offerings; private and public debt financings; as well as numerous mergers and acquisitions. Mr. Williams serves as a director of Alphatec Holdings, Inc., Impedimed Limited and Leading Biosciences, Inc. Mr. Williams served on the board of directors and is past President and Chairman of the San Diego Venture Group and has served on the board of directors of various charitable organizations in the communities in which he has lived. Mr. Williams is a graduate of Southern Illinois University with a B.S. degree.
Donald Williams自2016年6月起担任我们的董事会成员。Williams先生在Ernst & Young 担任18年的合伙人,过去7年担任Grant Thornton的合伙人。Williams先生的职业生涯集中在技术和生命科学领域的私营和上市公司。在Grant Thornton最近7年里,他曾担任Grant Thornton的生命科学实践的领导人和圣地亚哥办事处的执行合伙人。他是Ernst&Young和Grant Thornton在多个首次公开发行上的主要合伙人;二次发行;私人和公共债务融资;以及众多的兼并和收购。2014年开始,Williams 先生担任Marina Biotech, Inc.的董事。从2015年起,他担任Proove Biosciences,Inc。和Alphatec Holdings,Inc。及其全资子公司Alphatec Spine,Inc的董事。2001年至2014年,Williams先生在董事会任职,是 San Diego Venture Group 的前总裁和主席,并曾在他居住的社区的各种慈善组织的董事会任职。Williams先生是Southern Illinois University的毕业生。
Donald Williams has served as a member of our board of directors since June 2016. Mr. Williams is a 35-year veteran of the public accounting industry who retired in 2014. Mr. Williams spent 18 years as a partner at Ernst & Young and the last seven years as a partner at Grant Thornton. Mr. Williams’ career focused on private and public companies in the technology and life sciences sectors. During the last seven years at Grant Thornton, he served as the National Leader of Grant Thornton’s Life Sciences Practice and the Managing Partner of the San Diego Office. He was the lead partner for both Ernst & Young and Grant Thornton on multiple initial public offerings; secondary offerings; private and public debt financings; as well as numerous mergers and acquisitions. Mr. Williams serves as a director of Alphatec Holdings, Inc., Impedimed Limited and Leading Biosciences, Inc. Mr. Williams served on the board of directors and is past President and Chairman of the San Diego Venture Group and has served on the board of directors of various charitable organizations in the communities in which he has lived. Mr. Williams is a graduate of Southern Illinois University with a B.S. degree.

高管简历

中英对照 |  中文 |  英文
Clive Richardson

Clive Richardson,曾担任我们的首席运营官(2015年9月16日以来)。2014年1月至2015年9月,他曾担任Volution Immuno Pharmaceuticals SA的运营主管,作为顾问。任职Volution Immuno Pharmaceuticals SA之前,他曾担任Varleigh Immuno Pharmaceuticals的顾问(2007年公司创立以来)。任职Volution、Varleigh之前,他曾担任一系列国际医疗保健公司的董事会成员,其中包括CIS Healthcare Ltd.、Clinisys Ltd.。他此前曾担任Investec Bank的前任股票研究主管,也曾担任L.E.K.Consulting的战略顾问。他持有牛津大学三一学院(Trinity College、Oxford University)的动物性硕士学位。


Clive Richardson has served as our Chief Operating Officer and member of our board of directors since September 2015 as our Interim Chief Executive Officer from May 2018 until July 2019 and as our Chief Executive Officer since July 2019. Prior to that, Mr. Richardson was Head of Operations for Volution, a position he has held from January 2014 until September 2015 and before that he was a consultant to Volution’s predecessor company, Varleigh Immuno Pharmaceuticals, since inception in 2007. Prior to working for Volution and Varleigh, Mr. Richardson served as a member of the board of directors for a range of international healthcare companies, including CIS Healthcare Ltd. and Clinisys Ltd. Mr. Richardson was formerly Head of Equities Research for Investec Bank, and worked as a strategy consultant for L.E.K. Consulting. Mr. Richardson holds an M.A. in Zoology from Trinity College, Oxford University.
Clive Richardson,曾担任我们的首席运营官(2015年9月16日以来)。2014年1月至2015年9月,他曾担任Volution Immuno Pharmaceuticals SA的运营主管,作为顾问。任职Volution Immuno Pharmaceuticals SA之前,他曾担任Varleigh Immuno Pharmaceuticals的顾问(2007年公司创立以来)。任职Volution、Varleigh之前,他曾担任一系列国际医疗保健公司的董事会成员,其中包括CIS Healthcare Ltd.、Clinisys Ltd.。他此前曾担任Investec Bank的前任股票研究主管,也曾担任L.E.K.Consulting的战略顾问。他持有牛津大学三一学院(Trinity College、Oxford University)的动物性硕士学位。
Clive Richardson has served as our Chief Operating Officer and member of our board of directors since September 2015 as our Interim Chief Executive Officer from May 2018 until July 2019 and as our Chief Executive Officer since July 2019. Prior to that, Mr. Richardson was Head of Operations for Volution, a position he has held from January 2014 until September 2015 and before that he was a consultant to Volution’s predecessor company, Varleigh Immuno Pharmaceuticals, since inception in 2007. Prior to working for Volution and Varleigh, Mr. Richardson served as a member of the board of directors for a range of international healthcare companies, including CIS Healthcare Ltd. and Clinisys Ltd. Mr. Richardson was formerly Head of Equities Research for Investec Bank, and worked as a strategy consultant for L.E.K. Consulting. Mr. Richardson holds an M.A. in Zoology from Trinity College, Oxford University.
Ray Prudo

Ray Prudo,一直担任医疗保健公司的积极投资者和开发商25年。他一直担任Volution及其前身公司(Varleigh Immuno Pharmaceuticals)的创始人、董事长和首席执行官(2008年公司创立以来)。他目前是一些英国的医疗保健公司的董事会成员。他持有the University of London的内外全科医学士学位,以及the Royal College of Physicians and Surgeons of Canada的成员。


Ray Prudo has served as our Executive Chairman since September 2015. Dr. Prudo has been an active investor and developer of healthcare companies for 25 years. Dr. Prudo is the Founder, Chairman, and Chief Executive Officer of Volution and its predecessor company, Varleigh Immuno Pharmaceuticals, since inception in 2007. He is currently a board member of several UK healthcare companies. Dr. Prudo holds an MBBS from the University of London, and an FRCPC from the Royal College of Physicians and Surgeons of Canada.
Ray Prudo,一直担任医疗保健公司的积极投资者和开发商25年。他一直担任Volution及其前身公司(Varleigh Immuno Pharmaceuticals)的创始人、董事长和首席执行官(2008年公司创立以来)。他目前是一些英国的医疗保健公司的董事会成员。他持有the University of London的内外全科医学士学位,以及the Royal College of Physicians and Surgeons of Canada的成员。
Ray Prudo has served as our Executive Chairman since September 2015. Dr. Prudo has been an active investor and developer of healthcare companies for 25 years. Dr. Prudo is the Founder, Chairman, and Chief Executive Officer of Volution and its predecessor company, Varleigh Immuno Pharmaceuticals, since inception in 2007. He is currently a board member of several UK healthcare companies. Dr. Prudo holds an MBBS from the University of London, and an FRCPC from the Royal College of Physicians and Surgeons of Canada.